Insulin-like growth factor II plays a prominent role in malignant transformation by activating the IGF-I receptor. Activated IGF-IR promotes malignant growth by stimulating cellular proliferation and by inhibiting apoptosis. IGF-II also binds to the mannose 6-phosphate/IGF-II receptor (IGF-IIR), a transport molecule controlling IGF-II availability during embryogenesis. We hypothesize that the IGF-IIR also limits IGF-II signalling in malignant cells. In an autocrine model of IGF-II signalling, we demonstrated that IGF-IIR inhibited the extracellular accumulation of IGF-II, thereby reducing IGF-IR-dependent cellular proliferation and anchorage-independent growth. These observations lead us to propose the following research aims: l) To confirm that the IGF-IIR acts as an IGF-II antagonist by overexpressing the IGF-IIR with a panel of mutant IGF mutant peptides with altered receptor affinity. We anticipate that IGF-IIR overexpression, only when coexpressed with high IGF-IIR avidity ligands, will repress extracellular IGF availability; 2) IGF-IIR overexpression, suppressing IGF-II signalling, may provide a mechanism to reverse or inhibit IGF-II-dependent malignancy. We will test this hypothesis in IGF-II expressing sarcoma cell lines, 3) The third aim will further explore the antagonistic actions of IGF-IIR, employing receptor mutants with altered ligand binding and transport properties. Given that autocrine IGF-II expression is a prominent feature of sarcomas, for which treatment options are limited, investigation of a novel mechanism of growth factor suppression serves the long term goal of designing new therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
7R29CA067302-06
Application #
6417606
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1996-04-15
Project End
2002-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
6
Fiscal Year
2000
Total Cost
$63,602
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Derfoul, A; Robertson, N M; Hall, D J et al. (2000) The N-terminal domain of the mineralocorticoid receptor modulates both mineralocorticoid receptor- and glucocorticoid receptor-mediated transactivation from Na/K ATPase beta1 target gene promoter. Endocrine 13:287-95
DaCosta, S A; Schumaker, L M; Ellis, M J (2000) Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia 5:85-94
Ellis, M J; Jenkins, S; Hanfelt, J et al. (1998) Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 52:175-84
Oates, A J; Schumaker, L M; Jenkins, S B et al. (1998) The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 47:269-81